维普中文期刊产品整合服务
16篇 您的检索式:作者名="Finn SD"
    题名 作者 年代 出处 被引量
1Effect of candesartan on cause-specific mortality in heart failure patients:the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity(CHARM) program显示文摘Solomon SD Wang D Finn P 2004Circulation2004,110,:1
2Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention显示文摘Soloman SD McMurray JV Pfeffer MA Wittes J Fowler R Finn P 2005N Engl J Med2005,352,:1
3Effect of candesartan on causespecific mortality in heart failure patients: The candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program显示文摘Solomon SD Wang D Finn P 2004Circulation2004,110,:1
42007 chronic angina focused up date of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina 显示文摘Fraker TD Jr Finn SD Gibbons R J 2007J Am Coil Cardiol2007,50,23:1
5Early treatment of aquetiapine and sertraline overdose with Intralipid显示文摘Finn SD Uncles DR Willers J 2009An- aesthesia2009,64,2:1
6Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program 显示文摘SOLOMON SD WANG D FINN P 2004Circulation2004,110,15:1
7Cardiovascular risk of celecoxib in 6 ran- domized placebo-controlled trials : the cross trial safety analysis 显示文摘Solomon SD Wittes J Finn PV 2008Circula- tion2008,117,:1
8Effect of candesartan on cause specific mortality in heart failure patients:The candesartan in heart failure assessment of reduction in mortality and morbidity(CHARM) program显示文摘Solomon SD Wang D Finn P 0,,:1
9Cardio-vascular risk of celecoxib in 6 randomized placebo-controlled trials显示文摘Solomon SD Wittes J Finn PV 2008Circulation2008,117,16:1
10Stabilization to heat and protease degradation by complexing with antibody and by chemical modification显示文摘PAUL SD FINN W ROBERT BW 1974Biochim Biophys Acta1974,350,2:1
11Stabilization to Heat and protease degradation by complexing with antibody and by chemical modification显示文摘PAUL SD FINN W ROBERT BW 1974Biochim Biophys Aeta1974,350,2:1
12Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials:the cross trial safety analysis显示文摘Solomon SD Wittes J Finn PV 2008Circulation2008,117,16:1
13How doctors and patient discuss routine clinical deciftons: informed decision-naking in the outpatient setting 显示文摘BRADDOCK C H FINN SD LEVENSON W 1997J Gen Intern Mcd1997,12,:1
14Early treatment of a quetiapine and sertraline overdose with intralipid显示文摘Finn SD Uncles DR Willers J 0,,2:1
15Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention显示文摘Solomon SD McMurray JJV Pfeffer MA Wittes J Fowler R Finn P 2005N Engl J Med2005,352,:1
16Stabilization to heat and pro- tease degradation by complexing with antibody and by chemical modifi- cation显示文摘PAUL SD FINN W ROBERT BW 1974Bioehem Biaphys Aeta1974,350,2:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费